Introduction {#Sec1}
============

Atopic dermatitis (AD) is a chronic, inflammatory skin disease with an estimated prevalence of 7.3% in the US^[@CR1]^. The genetic background of chronic pruritus in AD is complex. The heritability of AD is estimated to be around 75%^[@CR2]^. Interestingly, when one or both parents have AD the risk of a child developing AD is higher than the risk of developing other atopic conditions, such as asthma and allergic rhinitis^[@CR3]^. This suggests that there are genetic factors specific to AD beyond those for general atopy^[@CR4]^.

One of the main functions of the skin is to act as a barrier between the individual and the environment, preventing water loss and at the same time preventing pathogen and allergen entry^[@CR5]^. Skin barrier dysfunction is a key clinical feature of AD, as this facilitates penetration of allergens, immunological dysfunction, and consequently an increased risk of developing eczema^[@CR5],[@CR6]^. The skin barrier dysfunction has been associated with the etiology of the itch-scratch cycle. Genes encoding skin barrier proteins have been shown to play a role in the heritability of AD^[@CR7],[@CR8]^. *FLG* is the most studied gene in AD. Loss of function (LOF) variants resulting in aberrant *FLG* production, constitute the best-known AD gene-association and have been shown to predispose individuals to AD^[@CR5],[@CR8]^. *FLG* initially synthesizes profilaggrin, which is then transformed to *FLG* monomers which interact with intermediate filaments in the stratum corneum (SC), causing such to aggregate into dense parallel arrays of macrofilaments. This promotes cellular compaction and keratin crosslinking in the SC, which forms a highly insoluble matrix that acts as a protective barrier^[@CR5],[@CR9]^.

The disrupted skin barrier of individuals harboring *FLG* LOF variants is characterized by dry and fissured skin. LOF variants in *FLG* are associated with lower levels of natural moisturizing factors in AD^[@CR10]^. This facilitates penetration of allergens, immunological dysfunction, and consequently an increased risk of developing eczema^[@CR5],[@CR6]^. Two prevalent *FLG* LOF variants, p.R501\* and p.S761fs were identified as causes of Ichthyosis vulgaris, (dry, thick, scaly skin), a common feature of moderate to severe AD^[@CR11],[@CR12]^. The allelic frequency of these variants in European cohort with eczema were estimated to be 2.8% and 6.6% for p.R501\* and p.S761fs respectively, with a combined frequency of 9.3%^[@CR13],[@CR14]^. They demonstrate the strongest association with AD, at 18% and 48% for moderate and severe disease, respectively^[@CR15]^. However, both the p.R501\* and p.S761fs variants, as well as the other two prevalent variants in Europeans, p.S324\* and p.R2447\*, are highly uncommon in Asian populations^[@CR16]--[@CR18]^. Furthermore, most of the identified *FLG* null variants display a higher prevalence in individuals of Caucasian ancestry as compared to the African Americans (27.5% vs. 5.8%)^[@CR19]^.

The genetic architecture of AD is likely a combination of common variants, but also rare LOF variants within the *FLG* and pathways involved^[@CR12]^. Several rare *FLG* LOF variants have been identified across different populations. For example, two rare LOF variants not found in European groups were identified in Asian AD populations, p.S2554\* and p.S1107fs (prevalence 4.2% and 1.4%, respectively)^[@CR16]^. Two studies in Singaporean Chinese AD populations identified a total of 14 additional *FLG* LOF variants^[@CR20],[@CR21]^.

Additional genes involved in skin barrier function are thought to have a potential role in AD. The epidermal differentiation complex (EDC) encodes proteins critical to the proper development of keratinocytes and normal formation of the skin barrier^[@CR22]^. The proteins in the EDC come from three gene families with closely related functions: the cornified envelop precursor family, and the S100 protein family and the S100 fused type proteins (SFTP)^[@CR22],[@CR23]^. *FLG*, which is located on chromosome 1q21, is a member of the SFTP family of the EDC^[@CR5]^. Dysregulation of other EDC genes has also been implicated in AD^[@CR24],[@CR25]^. Several profiling studies of the transcriptome have shown significant downregulation of EDC genes, such as *ivolucrin, loricrin* and *late cornified envelop 2B*, in AD^[@CR24]--[@CR26]^. For example, the deletion of the EDC member gene *Small Proline-Rich Protein 3* was shown to be associated with AD^[@CR27]^. Another large-scale genome-wide association study of AD patients also identified multiple risk loci in genes involved in epidermal proliferation and differentiation, in addition to a strong signal at the *FLG* locus^[@CR28]^.

Our work aimed to investigate the frequency and effect of rare *FLG* and EDC LOF variants on the age of onset, on the severity of the phenotype itself and on clinically relevant measures in AD. We also evaluated other potential risk loci within the entire EDC in patients with AD, participants of a clinical study, VP-VLY-686-2102 (also referred to as AD1 throughout this paper). Study AD1 was a randomized, double-blind, placebo-controlled, multicenter study of 168 patients (placebo or treatment) with chronic pruritus associated with AD. The genetic results from this study were then replicated in a subset of a second ongoing clinical study, EPIONE (also referred to as AD2 throughout this paper). Study AD2 was also a randomized, double-blind, placebo-controlled, ongoing multicenter study of patients with chronic pruritus associated with AD. We evaluate the effect of these variants on the age-of-onset of AD to further understand the penetrance and the consequences of these variants in the phenotype context.

Results {#Sec2}
=======

Incidence of FLG variants in AD patients {#Sec3}
----------------------------------------

In clinical studyAD1, whole genome sequencing data was obtained from 116 subjects. In an ongoing study AD2 a subset of 270 patient samples were collected and whole genome sequenced. Figure [1](#Fig1){ref-type="fig"} shows a PCA plot of the first study cohort 116/168, together with demographics and clinical characteristics of these patients provided in Supplementary Table [1](#MOESM2){ref-type="media"}. PCA was generated using WGS data, in order to examine population substructure of our studied cohort. Looking at panel B, we see enrichment of the two known variants in Caucasians and an interesting enrichment of other LOF *FLG* variants in the African American background. We investigated the incidence of all *FLG* LOF variants in the genomes of the clinical study patients, and compared them with the whole genome sequences of a control population of 316 healthy volunteers from clinical study 3107 (also referred to as JET8 throughout this paper). In AD1 study, 26 patients of the 116 (OR = 4.05, CI = 2.17--7.55, p \< 0.0001) samples carried *FLG* LOF variant. In study AD2, 41 of the 270 sampled patients carried a *FLG* LOF variant (OR = 1.99, CI = 1.18--3.36, p = 0.0093). In the control population from the JET8 study, 21 of the 316 sampled patients harbored *FLG* LOF variants. The presence of *FLG* LOF variants in the combined population of AD1 and AD2 patients was significantly greater than the presence of these variants in the JET8 control population (OR = 2.95, CI = 1.76--4.93, p \< 0.0001). The incidence of p.R501\* variant alone was examined in the AD1 cohort, and was found in 10 of the 116 patients (MAF = 0.043). GnomAD's allelic frequency total is 0.009 with the highest allelic frequency noted for European (Non-Finnish) population. The list of all the identified *FLG* LOF is present in Table [1](#Tab1){ref-type="table"} and displayed on Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. Figure [2](#Fig2){ref-type="fig"} displays the location of individual LOF variant in both AD sets. We do observe a higher frequency of *FLG* LOF variants with many being rare singleton variants when compared to controls as displayed on Fig. [3](#Fig3){ref-type="fig"}. In addition, we have evaluated the presence of *FLG* population specific variants in gnomAD across ethnicities as shown on Fig. [4](#Fig4){ref-type="fig"}. Figure [4](#Fig4){ref-type="fig"} shows the major frequency differences among populations especially when focusing the most actionable variants. Panel 4a. displays the frequent variants in the entire region whereas Panel B. displays truncating variants in the region \<1500 aa. The motivation beyond examining truncation in the context of *FLG* LOFs was to explore physical truncation of the protein that would otherwise provide monomers as well as exploring the incidence of such.Figure 1PCA plot displaying the population structure of AD1 cohort. (**A**) PCA plot colored by variant status. (**B**) PCA plot (WGS data) colored by ethnicity.Table 1All LOF in *FLG* identified in the AD set.Patient IDEthnicityGeneTranscript IDNT changeAA changeRSziDChromosomeStart_PositionEnd_Position1011019Asian*FLG*NM_002016c.C8117Gp.S2706\*rs54279902611522792451522792451081007Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850771091012African American*FLG*NM_002016c.5799delGp.R1933fsrs54810379111522815631522815631241019Asian*FLG*NM_002016c.C8117Gp.S2706\*rs54279902611522792451522792451451005Asian*FLG*NM_002016c.7487delCp.T2496fsrs37527767011522798751522798751471013Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858611531004Caucasian*FLG*NM_002016c.10137delGp.R3379fs.11522772251522772251601018Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858611601033Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850771601033Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858611601038African American*FLG*NM_002016c.7740_7741delp.S2580fsrs75077044911522796211522796211621005African American*FLG*NM_002016c.C2476Tp.R826\*rs11574636311522848861522848861631028Caucasian*FLG*NM_002016c.C9077Gp.S3026\*rs142654256211522782851522782851631028Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858611711007African American*FLG*NM_002016c.C2404Tp.Q802\*rs15061195311522849581522849581711027Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858611721001Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850771721003Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850771721003Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586142973718Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs558269137115228507715228507742978887Asian*FLG*NM_002016c.7487delCp.T2496fsrs375277670115227987515227987542989053African American*FLG*NM_002016c.C2476Tp.R826\*rs115746363115228488615228488642989254Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143022549African American*FLG*NM_002016c.C7339Tp.R2447\*rs138726443115228002315228002343022550Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143050811African American*FLG*NM_002016c.C5717Ap.S1906\*rs141784184115228164515228164543055206Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs558269137115228507715228507743062910Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143079509African American*FLG*NM_002016c.C6692Ap.S2231\*rs536240526115228067015228067043099438Caucasian*FLG*NM_002016c.C7339Tp.R2447\*rs138726443115228002315228002343099528African American*FLG*NM_002016c.C6692Ap.S2231\*rs536240526115228067015228067043109908Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143116759Caucasian*FLG*NM_002016CNV_DELETIONCNV_DELETIONCNV_DELETION115227465215229768043132454Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143134422Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143135174Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143148497Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs558269137115228507715228507743179517Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs558269137115228507715228507743198393Caucasian*FLG*NM_002016c.4020delAp.G1340fsrs770008928115228334115228334243203074African American*FLG*NM_002016c.2282_2285delp.S761fsrs558269137115228507715228507743221146Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143221147Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143260548Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs558269137115228507715228507743297049Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs61816761115228586115228586143306754African American*FLG*NM_002016c.C2476Tp.R826\*rs11574636311522848861522848865500365697Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850775502137729African American*FLG*NM_002016c.C9077Gp.S3026\*rs142654256211522782851522782855502362305African American*FLG*NM_002016c.C9947Gp.S3316\*rs14948491711522774151522774155502362305African American*FLG*NM_002016c.C2476Tp.R826\*rs11574636311522848861522848865502432960African American*FLG*NM_002016c.C5392Tp.R1798\*rs14910555111522819701522819705504556880Caucasian*FLG*NM_002016c.C7339Tp.R2447\*rs13872644311522800231522800235504556880Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858615505347456Caucasian*FLG*NM_002016c.C1501Tp.R501\*rs6181676111522858611522858615505609600Asian*FLG*NM_002016c.C7661Gp.S2554\*rs12190962611522797011522797015506294081Caucasian*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850775507409104African American*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850775508687105African American*FLG*NM_002016c.C9947Gp.S3316\*rs14948491711522774151522774155508688512Caucasian*FLG*NM_002016c.7487delCp.T2496fsrs37527767011522798751522798755512912848Caucasian*FLG*NM_002016c.C11227Tp.R3743\*rs14242164411522761351522761355514977857African American*FLG*NM_002016c.2282_2285delp.S761fsrs55826913711522850771522850775515794176Caucasian*FLG*NM_002016c.C7339Tp.R2447\*rs13872644311522800231522800235515801488Asian*FLG*NM_002016c.G7264Tp.E2422\*rs37458879111522800981522800985515801488Asian*FLG*NM_002016c.7214_7215delp.A2405fs.11522801471522801475515862528Asian*FLG*NM_002016c.A12064Tp.K4022\*rs14646624211522752981522752985515996305Asian*FLG*NM_002016c.C3418Tp.R1140\*rs14137526011522839441522839445516026753Asian*FLG*NM_002016c.C11227Tp.R3743\*rs14242164411522761351522761355516124672Asian*FLG*NM_002016c.3321delAp.S1107fsrs2005197811152284041152284041Figure 2Lollipop plot displays the location and frequency of the identified variants in *FLG*. We observe an enrichment of rare LOF variants in *FLG* detected in AD patients, Red rectangles are *FLG* repeats.Figure 3Comparison of variants detected in cases (AD -- blue) and controls (JET8 - orange). We observe higher frequency of *FLG* variants in AD. The variants identified in AD cases not detected in controls are marked with a\*.Figure 4Prevalent *FLG* variants across ethnicities. MAF is displayed on the y-axis whereas the ethnicities are displayed on the x-axis. Panel A displays any truncation whereas Panel B displays truncation \<1500 aa.

Enrichment of rare LOF variants in the EDC in AD patients {#Sec4}
---------------------------------------------------------

The incidence of rare LOF variants in the EDC was investigated. Specifically, evolutionarily related members of the S100 fused type proteins (SFTP) family were evaluated, such as CRNN, *FLG2*, *HRNR* and *RPTN*, among other EDC genes all listed Table [2](#Tab2){ref-type="table"} and LOF in EDC displayed on Fig. [5](#Fig5){ref-type="fig"}. We investigated the frequency and effect of rare LOF (stopgain, frameshift, splicing) variants in the SFTP gene family in the AD1 population compared to the JET8 controls, as defined by a MAF \< 5%. In the AD1 cohort, 45 of the 116, 38% AD patients carry a LOF variant (Table [2](#Tab2){ref-type="table"}). In the AD2 cohort 75 of the 270, 27.7% AD patients carry a LOF variant. In the JET8 controls, 55 of the 316, 17% patients carried these LOF variants. Comparing these two results, the presence of these variants is significantly higher in the AD patients than the controls (OR = 2.18, CI = 1.51--3.13, p \< 0.0001). Cumulative risks (OR and RR) were calculated for these rare variants as well, based on the presence of at least one deleterious allele. The relative risk (RR) for the rare SFTP LOF SNPs (n = 13) was found to be 2.27 (p = 0.0005). The OR was found to be 2.66 (p = 0.0007). In addition we computed the genetic risk score of these top variants shown on S Fig. [2](#MOESM1){ref-type="media"}. with a p-value of 0.00001. We were able to replicate the effect in the AD2 study cohort, OR 2.11, p-value = 0.022.Table 2ALL EDC LOFs identified in the AD set.Patient IDEthnicity*Gene*Transcript IDNT changeAA changeRSziDChromosomeStart_PositionEnd_Position5500098961Caucasian*FLG2*NM_001014342c.5475_5478delp.T1825fs.11523247841523247845508687105African American*FLG2*NM_001014342c.C5399Gp.S1800\*rs134943424911523248631523248631641003African American*FLG2*NM_001014342c.C5399Gp.S1800\*rs134943424911523248631523248631601037African American*FLG2*NM_001014342c.3940_3941insTAp.T1314fsrs56718408411523263211523263211771002Caucasian*FLG2*NM_001014342c.C380Ap.S127\*rs373458772115232988215232988243102554African American*FLG2*NM_001014342c.3940_3941insTAp.T1314fsrs56718408411523263211523263211601035African American*HRNR*NM_001009931c.8467delAp.S2823fsrs144106315211521856381521856385508393600Caucasian*HRNR*NM_001009931c.C2299Tp.R767\*rs14845973311521918061521918065505310928Caucasian*HRNR*NM_001009931c.C2299Tp.R767\*rs14845973311521918061521918065500363216Caucasian*HRNR*NM_001009931c.C2299Tp.R767\*rs14845973311521918061521918061711017African American*HRNR*NM_001009931c.C2299Tp.R767\*rs14845973311521918061521918061061004Caucasian*HRNR*NM_001009931c.C2299Tp.R767\*rs148459733115219180615219180642989053African American*HRNR*NM_001009931c.C2299Tp.R767\*rs148459733115219180615219180643306754African American*HRNR*NM_001009931c.C2299Tp.R767\*rs14845973311521918061521918061721003Caucasian*LCE2C*NM_178429c.C96Ap.C32\*rs411957711526485871526485875512683728Caucasian*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815605509505040African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815605506327056African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815605502328576African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815605502137729African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601681005African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601651002African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601641003African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601601035African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601511001African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601431001African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815601371007African American*LCE4A*NM_178356c.C9Ap.C3\*rs14776524011526815601526815605506294081Caucasian*LCE4A*NM_178356c.245_254delp.G82fsrs763134811115268179615268179642989053African American*LCE4A*NM_178356c.C9Ap.C3\*rs147765240115268156015268156043062909African American*LCE4A*NM_178356c.C9Ap.C3\*rs147765240115268156015268156043181943Caucasian*LCE5A*NM_178438c.C235Tp.R79\*rs228229811524842451524842455502328576African American*RPTN*NM_001122965c.C2227Tp.R743\*rs18495207511521273481521273481631025African American*RPTN*NM_001122965c.C2227Tp.R743\*rs18495207511521273481521273485511537345Caucasian*RPTN*NM_001122965c.C1861Tp.Q621\*rs75133051511521277141521277145515993537Caucasian*S100A16*NM_001317007c.C5Gp.S2\*rs137911276115358062315358062343179516Caucasian*S100A3*NM_002960c.208delGp.V70fsrs57602293711535202551535202551511001African American*SPRR3*NM_001097589c.189_205delp.E63fsrs74608007411529756851529756851451006African American*SPRR3*NM_001097589c.189_205delp.E63fsrs74608007411529756851529756851371005African American*SPRR3*NM_001097589c.189_205delp.E63fsrs746080074115297568515297568543079509African American*SPRR3*NM_001097589c.189_205delp.E63fsrs746080074115297568515297568543128537African American*SPRR4*NM_173080c.22_23insAp.R8fsrs201207143115294438815294438843153173African American*SPRR4*NM_173080c.22_23insAp.R8fsrs20120714311529443881529443885508393600Caucasian*TCHH*NM_007113c.C4309Tp.Q1437\*rs37767796011520813841520813841611010Caucasian*TCHH*NM_007113c.C991Tp.Q331\*rs201930497115208470215208470243050811African American*TCHH*NM_007113c.1delAp.M1fsrs74814658211520865551520865555508457168Caucasian*TCHHL1*NM_001008536c.C2686Tp.Q896\*rs14811333411520574721520574725516026753Asian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925514715841Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925511537345Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925508719312Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925508456912Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925508456784Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925507675024Asian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925506589377Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581921711004Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581921601032Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581921481008Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581921301005African American*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581921131007Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581921011018Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs15001495811520581921520581925508687105African American*TCHHL1*NM_001008536c.C880Tp.Q294\*rs6174931611520592781520592785502362305African American*TCHHL1*NM_001008536c.C880Tp.Q294\*rs6174931611520592781520592781371007African American*TCHHL1*NM_001008536c.C880Tp.Q294\*rs61749316115205927815205927843022549African American*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs150014958115205819215205819243099438Caucasian*TCHHL1*NM_001008536c.C1966Tp.Q656\*rs150014958115205819215205819243079509African American*TCHHL1*NM_001008536c.C880Tp.Q294\*rs61749316115205927815205927843099528African American*TCHHL1*NM_001008536c.C880Tp.Q294\*rs617493161152059278152059278Figure 5Percentage of LOF variants identified in both AD cohorts in the EDC (with high incidence of LOFs identified in the SFTP family). The empty gray boxes indicate no alteration whereas the filled gray boxes indicate alteration (LOF) present in a particular subject in that particular gene. The spatial distribution displays all the patients carrying at least a single variant in the queried genes.

Regional enrichment analysis reiterates the significance of the locus {#Sec5}
---------------------------------------------------------------------

In order to study the LOF variant set of the whole SFTP family of the EDC, an optimal unified sequence kernel association test (SKAT-O) was used. This test was applied to compare the WGS's of AD1 cases versus healthy controls. Overall, a significant accumulation of rare variants in the EDC was observed in AD cases when compared to controls (p = 4.7E-20). This value is notably much lower than the association of *FLG* alone (p = 4.5E-6). Specifically, *en masse SKATO* analysis showed highly significant association with AD in *HRNR* looking beyond mere *FLG*, genes. Accumulation of rare LOF variants in the EDC yields a p-value of 4.7e-20, much lower than for *FLG* alone p-value of 4.5e-6 (LOF set comparing AD with controls) and reiterates the importance of looking for LOF variants extending beyond *FLG* itself.

Association of variant status with age-of-onset of AD {#Sec6}
-----------------------------------------------------

We collected age of onset of AD information for the whole genome sequencing (WGS) samples also genotyped for 2 most prevalent *FLG* variants (p.R501\* (rs61816761), p.S761fs (rs558269137)). The average age of onset in this cohort is 23.2 years of age (S Fig. [3](#MOESM1){ref-type="media"}. Histogram of age of onset). We observe a significant association between *FLG* LOF status and age-of-onset, with earlier age of onset of AD observed in the *FLG* LOF carrier group (p-value 0.0003, Wilcoxon two-sample test).The median age of onset for WT is 20 years of age, and the mean age of onset is 4.

Interestingly, the effect is even stronger when considering all detected *FLG* LOF variants. Having two or more *FLG* LOF variants associates with onset of AD at 2 years of age (Wilcoxon Two-Sample Test). We observe a significant association between *FLG* LOF status and age-of-onset, with earlier age of onset of AD observed in the *FLG* LOF carrier group (*z*-score 3.95, *p-value* 0.00008) with the effect displayed on Fig. [6](#Fig6){ref-type="fig"}. The OR of having onset before 20 years of age in the AD population if the subject is a variant carrier is 8.9 (p-value 0.004). The OR of having onset before 5 years of age in the AD population if the subject is a variant carrier is 7.8 (p-value 0.0001). We have shown a significant enrichment of WGS for rare variants in the EDC region in cases compared with controls. Age-of-onset analysis shows not only the effect of the *FLG* and likely EDC variants in terms of heightened risk of AD, but foremost enables to predict early onset, lending further credence to the penetrance and causative effect of the identified variants.Figure 6AD Age-of-onset box-plot of AD. We observe an earlier age-of-onset of AD in *FLG* LOF variant carriers. The effect is greater with higher frequency of FLG LOFs.

Discussion {#Sec7}
==========

Using screening methods that are dependent only on a subset of known *FLG* variants (p.R501\*, p.S761fs etc.) we are missing out on \~30% of *FLG* LOF variation. Whole Genome Sequencing closes that gap of missing *FLG* impairment among AD patients. It is especially evident among non-European populations as shown in Figs. [1](#Fig1){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. With whole genome sequencing and focusing on all LOF variants we have shown that we can explain a higher proportion of patients as well as find other actionable variants (variants of well-established consequence on development and persistence of AD, that can guide diagnosis and likely therapeutic approaches) that are variable across populations. The same holds true when we expand to pathway based analyses and EDC complex, in example variants in *HRNR* and other SFTP family members.

It has been previously reported by Margolis *et al*., that subjects with an *FLG* variants were less likely (OR 0.54) to report as 'symptom free' in comparison with those without these variants. Interestingly, children in that cohort carrying the p.R501\* variant (OR 0.44) were more likely to be non-responders to therapies^[@CR19]^. Another interesting study reported by Koseki *et al*., investigating the effect of 8 LOF *FLG* variants, supports the notion that the effect of *FLG* LOFs variants is prominent during a very early stage of life^[@CR29]^. Further evidence comes from another study focusing specifically on 2282del4 showing association with AD developed during infancy as reported by Rupnik *et al*.^[@CR30]^. Furthermore, the authors showed an association with longer duration and more frequent hospitalization in this cohort of *FLG* variant carriers^[@CR30]^. It is becoming more apparent that *FLG* and overall EDC, specifically SFTP variants predispose to risk of AD with effects differing across ages.

We used *FLG* and EDC status of variants and used that to correlate with age-of-onset and other clinical measures of AD and itch. The fact that age-of-onset is highly correlated with *FLG* status reflects upon the potential causes of the disorder itself, here likely skin barrier dysfunction as primary. The fact that frequency matters and amplifies the observed earlier onset lends credence to yet another hypothesis were the effect is intensified with number of causative variants.

There are several limitations of this work that may impact the conclusions as of course we extrapolate to EDC but there could be other ways of assigning pathway based categories that are involved in skin barrier function. Noteworthy is also the fact that we are not using controls evaluated for not having AD, so likely the magnitude of the effect would be even greater with such matched and screened for not having AD diagnosis set of controls. Nevertheless, it is likely that directionally our conclusions are valid and simply the magnitude may increase with differently matched controls. As we are accruing more subjects it will be very interesting to design a panel that would cover and work for different ethnicities as the majority of variants discussed in literature are applicable to Caucasian ancestry. It will also be relevant to quantify the effects of these variants on a translational basis looking at skin proteomics. In addition structural variants that are usually known to account for roughly 5% of the variation unexplained, should be evaluated, in this context to provide a more comprehensive outlook on the role of skin barrier genetics in AD.

Conclusion {#Sec8}
==========

Understanding the genetic background and risk of early-onset is suggestive of skin barrier dysfunction etiology of the itch-scratch cycle present in early-onset AD. The pervasive effect of the variants would likely then manifest itself at an early age with AD phenotype of xerosis, and susceptibility to infection. Novel hence newly discovered LOF variants detected in this study expand the pool of risk loci. Whole-genome sequencing showed enrichment for rare variants in the EDC, specifically in the SFTP family, in AD patients compared to healthy controls. The strong association between these variants and AD suggests they may significantly affect a person's risk of developing the disease. Further, these variants identified are often in genes that affect the skin barrier, lending evidence to the role of barrier dysfunction in the pathogenesis of AD. The novel LOF variants detected in this study help explain the missing heritability and etiology of AD and could serve as disease biomarkers, which could personalize treatment to improve disease outcomes. Adding the age component further reiterates the heritable component with an intensified effect and earlier onset observed at a young age and higher frequency of the LOF variants.

Methods {#Sec9}
=======

Clinical study design {#Sec10}
---------------------

The clinical studies VP-VLY-686-2102 and VP-VLY-686-3101 were multicenter, randomized, placebo-controlled, double-blind clinical studies in the United States. Participants provided written informed consent and were provided a copy of the signed consent form. All the studies were approved by the Advarra IRB located in Columbia, MD, USA and participants consented to participation in all the aspects of the studies. Methods were performed in accordance with the relevant guidelines and regulations, in adherence to the IRB approved protocol. Pharmacogenetic samples were taken at the screening visit for both studies. In EPIONE1, the self-reported age of onset was collected by the Medical History of Atopy questionnaire (developed by Vanda) at the first study visit. The study was divided into two phases: the screening phase and the evaluation phase (S Fig. [1](#MOESM1){ref-type="media"}).

Key study inclusion criteria included: chronic itch related to AD, defined as lasting 6 weeks or longer, that was refractory to previous treatment by patient history, average itch visual analog score (VAS) of greater than or equal to 70 mm out of 100 mm, and itch verbal response score (VRS) of greater than or equal to 3 on at least one of the past three days prior to randomization.

Study demographics were similar between treatment and placebo groups for sex, age, race and baseline itch and disease measures (S. Table [1](#MOESM2){ref-type="media"}).

DNA quantification {#Sec11}
------------------

Incoming nucleic acid samples are quantified using fluorescent-based assays (PicoGreen) to accurately determine whether sufficient material is available for library preparation and sequencing.

DNA integrity {#Sec12}
-------------

DNA sample size distributions are profiled by a Fragment Analyzer (Advanced Analytics) or BioAnalyzer (Agilent Technologies), to assess sample quality and integrity.

Genotyping {#Sec13}
----------

At the NYGC, we run the HumanCoreExome 24v1.3 array for all human DNA samples that we sequence.

WGS library preparation and sequencing, Truseq PCR-free (450 bp) {#Sec14}
----------------------------------------------------------------

Whole genome sequencing (WGS) libraries were prepared using the Truseq DNA PCR-free Library Preparation Kit.

### WGS Germline analysis part I {#Sec15}

Whole Genome data were processed on NYGC automated pipeline. Paired-end 150 bp reads were aligned to the GRCh37 human reference (BWA-MEM v0.7.8) and processed with GATK best-practices workflow (GATK v3.4.0).

The mean coverage in the *FLG* region is 35.8, it reflects the samples average. The coverage for the *FLG* region tracks with the coverage for the whole genome. The coverage information per *FLG* region per sample is provided in the Supplementary File.

All high quality variants obtained from GATK were annotated for functional effects (intronic, intergenic, splicing, nonsynonymous, stopgain and frameshifts) based on RefSeq transcripts using Annovar (<http://www.openbioinformatics.org/annovar/>)^[@CR31]^. Additionally, annovar was used to match general population frequencies from public databses (Exac, GnomAD, ESP6500, 1000 g) and was used to prioritize rare, loss-of-function variants.

### Genomic data analysis part II {#Sec16}

All variants in *FLG* and EDC were identified in whole genome sequencing data. The two most known genetic risk factors as defined by p.R501\* (rs61816761), p.S761fs (rs558269137) were in addition verified with genotyping (S Fig. [4](#MOESM1){ref-type="media"}). All analyses were conducted in PLINK, MATLAB. In order to proceed with burden testing, we selected variants based on their quality, ancestry and pathogenicity, creating a subset of high-confidence variants. Variants that met these quality and pathogenicity filters were used for burden testing versus a. internal controls and b. Genome Aggregation Database (gnomAD).

Supplementary information
=========================

 {#Sec18}

Supplementary Material. Supplementary Dataset 1.
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